CYP2C19 pharmacogenetics in cancer: The effect of disease progression
Registration number:
|
ACTRN12609000056291 |
Ethics number:
|
NTX/08/07/060 |
The aim of this study is to determine whether compromised CYP2C19 activity occurs
at all stages of disease or whether activity declines as cancer progresses. Such
a decline in activity could influence the response to therapy in the same patient
at different stages of disease.
Progress
Open
Results
None to date
Centres involved
- The University of Auckland
